Full Text Journal Articles in
Journal Clin Cancer Res

Advertisement

Find full text journal articles






News FLASH-RT: To Treat GBM and Spare Cognition, Fraction Size and Total Dose Matter.

Christina C Huang, Marc S Mendonca,

Data indicate that ultra-high dose rate (>10<sup>6</sup> Gy/s) FLASH-RT delivery of radiation reduces normal tissue damage without compromising tumor response. Orthotopic glioblastoma mouse studies now demonstrate that radiation fraction size, total dose, and number of fractions are critical parameters for FLASH-RT cognitive sparing without compromising tumor response. ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



An Immune Risk Score Predicts Survival of Patients with Acute Myeloid Leukemia Receiving Chemotherapy.

Yun Wang, Yan-Yu Cai, Tobias Herold, Run-Cong Nie, Yu Zhang, Robert Peter Gale, Klaus H Metzeler, Yun Zeng, Shun-Qing Wang, Xue-Yi Pan, Tong-Hua Yang, Yuan-Bin Wu, Qing Zhang, Zhi-Jun Wuxiao, Xin Du, Zhi-Wei Liang, Yong-Zhong Su, Jing-Bo Xu, Yong-Qing Wang, Ze-Lin Liu, Jian-Wei Wu, Xiong Zhang, Bing-Yi Wu, Ruo-Zhi Xiao, San-Bin Wang, Jin-Yuan Li, Pei-Dong Chi, Qian-Yi Zhang, Si-Liang Chen, Zhe-Yuan Qin, Xin-Mei Zhang, Na Zhong, Wolfgang Hiddemann, Qi-Fa Liu, Bei Zhang, Yang Liang,

<b>Purpose:</b>Prediction models for acute myeloid leukemia (AML) are useful, but have considerable inaccuracy and imprecision. No current model includes covariates related to immune cells in the AML microenvironment. Here, an immune risk score was explored to predict the survival of patients with AML.<br><br><b>Experimental design:</b>We evaluated the predictive accuracy of several ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Metastatic Genitourinary Cancer Patients.

Heather J Chalfin, Tiziano Pramparo, Amir Mortazavi, Scot A Niglio, Joseph D Schonhoft, Adam Jendrisak, Yen-Lin Chu, Robin Richardson, Rachel Krupa, Amanda K L Anderson, Yipeng Wang, Ryan Dittamore, Sumanta K Pal, Primo N Lara, Mark N Stein, David I Quinn, Seth M Steinberg, Lisa M Cordes, Lisa Ley, Marissa Mallek, Olena Sierra Ortiz, Rene Costello, Jacqueline Cadena, Carlos Diaz, James L Gulley, William Dahut, Howard Streicher, John J Wright, Jane B Trepel, Donald P Bottaro, Andrea B Apolo,

<b>Purpose:</b>Circulating tumor cells (CTCs) are under investigation as a minimally invasive liquid biopsy that may improve risk stratification and treatment selection. CTCs uniquely allow for digital pathology of individual malignant cell morphology and marker expression. We compared CTC features and T-cell counts with survival endpoints in a cohort of metastatic ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Modification of extracellular matrix enhances oncolytic adenovirus immunotherapy in glioblastoma.

Juri Kiyokawa, Yoichiro Kawamura, Shanawaz M Ghouse, Simge Acar, Erinc Barcin, Jordi Martínez-Quintanilla, Robert L Martuza, Ramon Alemany, Samuel D Rabkin, Khalid Shah, Hiroaki Wakimoto,

PURPOSE:Extracellular matrix (ECM) component hyaluronan (HA) facilitates malignant phenotypes of glioblastoma (GBM), however, whether HA impacts response to GBM immunotherapies is not known. Herein, we investigated whether degradation of HA enhances oncolytic virus immunotherapy for GBM. EXPERIMENTAL DESIGN:Presence of HA was examined in patient and murine GBM. Hyaluronidase-expressing oncolytic adenovirus ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Early adaptation of colorectal cancer cells to the peritoneal cavity is associated with activation of 'stemness' programs and local inflammation.

Jorge Barriuso, Raghavendar Thyagaraja Nagaraju, Shreya Belgamwar, Bipasha Chakrabarty, George J Burghel, Helene Schlecht, Lucy Foster, Elaine Kilgour, Andrew J Wallace, Michael Braun, Caroline Dive, D Gareth Evans, Robert G Bristow, Mark P Saunders, Sarah T O'Dwyer, Omer Aziz,

PURPOSE:At diagnosis, colorectal cancer presents with synchronous peritoneal metastasis in up to 10% of patients. The peritoneum is poorly characterized with respect to its super-specialised microenvironment. Our aim was to describe the differences between peritoneal metastases and their matched primary tumours excised simultaneously at the time of surgery. Also, we ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



FGFR inhibition overcomes resistance to EGFR-targeted therapy in epithelial-like cutaneous carcinoma.

Adrià Bernat-Peguera, Juan Navarro-Ventura, Laura Lorenzo-Sanz, Victoria da Silva-Diz, Mattia Bosio, Luis Palomero, Rosa M Penin, Diana Pérez Sidelnikova, Josep Oriol Bermejo Segú, Miren Taberna, Noelia Vilariño, Josep Maria Piulats, Ricard Mesia, Joan Maria Viñals, Eva González-Suárez, Salvador Capella-Gutierrez, Alberto Villanueva, Francesc Viñals, Purificación Muñoz,

<b>Purpose:</b>Recurrent and/or metastatic unresectable cutaneous squamous cell carcinomas (cSCCs) are treated with chemotherapy or radiotherapy but have poor clinical responses. A limited response (up to 45% of cases) to EGFR-targeted therapies was observed in clinical trials with advanced and metastatic cSCC patients. Here, we analyze the molecular traits underlying the ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.

Takako Eguchi Nakajima, Shigenori Kadowaki, Keiko Minashi, Tomohiro Nishina, Takeharu Yamanaka, Yuichiro Hayashi, Naoki Izawa, Kei Muro, Shuichi Hironaka, Takeshi Kajiwara, Yutaka Kawakami,

<b>Purpose:</b>We conducted a phase I/II study to investigate the safety and efficacy of nivolumab (NIVO) with paclitaxel (PTX) plus ramucirumab (RAM).<br><br><b>Experimental design:</b>Patients with advanced gastric cancer (AGC) refractory to first-line chemotherapy were included. Patients received NIVO (3 mg/kg on days 1 and 15) combined with PTX (80 mg/m2 on days ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Deep learning predicts HPV-association in oropharyngeal squamous cell carcinomas and identifies patients with a favorable prognosis using regular H&E stains.

Sebastian Klein, Alexander Quaas, Jennifer Quantius, Heike Löser, Jörn Meinel, Martin Peifer, Steffen Wagner, Stefan Gattenlöhner, Claus Wittekindt, Magnus von Knebel Doeberitz, Elena-Sophie Prigge, Christine Langer, Ka-Won Noh, Margaret Maltseva, Hans Christian Reinhardt, Reinhard Büttner, Jens Peter Klussmann, Nora Wuerdemann,

<b>Purpose:</b>Human papillomavirus (HPV) in oropharyngeal squamous cell carcinoma (OPSCC) is tumorigenic and has been associated with a favorable prognosis compared to OPSCC caused by tobacco, alcohol, and other carcinogens. Meanwhile, machine learning has evolved as a powerful tool to predict molecular- and cellular alterations of medical images of various sources.<br><br><b>Experimental ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs.

Paul G Kluetz, Patricia Keegan, George D Demetri, Katherine A Thornton, Joohee Sul, Janice Kim, Harvey Katzen, Laurie Beth Burke, R Donald Harvey, Elleni Alebachew, Sundeep Agrawal, Abhilasha Nair, Martha Donoghue, William F Pierce, Stacy Shifflett Shord, Jennifer J Gao, Richard Pazdur,

The U.S. Food and Drug Administration (FDA) conducts independent reviews of scientific data obtained with investigational drug products to ensure that they are safe and effective. As a result of this process, FDA-approved product labeling is generated that is considered one of the most trusted sources of information for use ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



WORLD CANCER RESEARCH DAY: A call to action for a coordinated international research effort to prevent, diagnose and treat cancer.

Marta Puyol, Joan Seoane, Esther Aguilar, Lisa B Vozza, Isabel Orbe, Katherine H Crawford, Ana Fernández, Freddie Bray, Sonali E Johnson, Satish Gopal,

Cancer is a major public health problem and the second leading cause of death worldwide. The burden of cancer continues to grow and is projected to double by 2040. This situation calls for coordinated action and emphasizes the need to join efforts on worldwide initiatives, including World Cancer Research Day ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Phase 1 and pharmacological study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer.

Rosemarie de Haan, Michel Van den Heuvel, Judi van Diessen, Heike M U Peulen, Erik van Werkhoven, Adrianus Johannes de Langen, Ferry Lalezari, Dick Pluim, Manon Verwijs-Janssen, Conchita Vens, Jan H M Schellens, Neeltje Steeghs, Marcel Verheij, Baukelien Van Triest,

<b>Purpose:</b>To identify a maximum tolerated dose (MTD) of the PARP inhibitor olaparib in combination with loco-regional radiotherapy with/without cisplatin for the treatment of non-small cell lung cancer (NSCLC).<br><br><b>Patients and methods:</b>Olaparib dose was escalated in two groups: radiotherapy (66Gy/24 fractions, 2.75Gy/fraction) with and without daily cisplatin (6mg/m2), using Time-to-Event Continual Reassessment ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Preclinical Characterization of HPN536, a Trispecific, T Cell-activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors.

Mary Ellen Molloy, Richard J Austin, Bryan D Lemon, Wade H Aaron, Vaishnavi Ganti, Adrie Jones, Susan D Jones, Kathryn L Strobel, Purbasa Patnaik, Kenneth Sexton, Laurie Tatalick, Timothy Z Yu, Patrick A Baeuerle, Che-Leung Law, Holger Wesche,

<b>Purpose:</b>Mesothelin (MSLN) is a GPI-linked tumor antigen overexpressed in a variety of malignancies, including ovarian, pancreatic, lung and triple-negative breast cancer. Early signs of clinical efficacy with MSLN-targeting agents have validated MSLN as a promising target for therapeutic intervention, but therapies with improved efficacy are still needed to address the ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer (mTNBC).

Tanya E Keenan, Tianyu Li, Tuulia Vallius, Jennifer L Guerriero, Nabihah Tayob, Bose S Kochupurakkal, Janae Davis, Ricardo G Pastorello, Rie K Tahara, Leilani Anderson, Jake Conway, Meng Xiao He, Erin Shannon, Robert Godin, Peter K Sorger, Alan D D'Andrea, Beth Overmoyer, Eric P Winer, Elizabeth A Mittendorf, Eliezer M Van Allen, Geoffrey I Shapiro, Sara M Tolaney,

PURPOSE:We report results from a phase II study assessing the efficacy of the WEE1 inhibitor adavosertib with cisplatin in metastatic triple-negative breast cancer (mTNBC). EXPERIMENTAL DESIGN:Patients with mTNBC treated with 0-1 prior lines of chemotherapy received cisplatin 75 mg/m<sup>2</sup> IV followed 21 days later by cisplatin plus adavosertib 200 mg ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Antibody peptides as cancer vaccine - turning weapons to targets.

Martina Seiffert,

Stereotyped B-cell receptors (BCRs) are frequent in patients with chronic lymphocytic leukemia (CLL). In vitro and in mouse models of CLL, immunogenic epitopes of these BCRs were shown to trigger specific T-cell responses and to control leukemia development. These results suggest vaccination with autologous BCR-derived peptides as a novel therapy ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Selected Articles from This Issue.

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, 26(23):6075]

Cited: 0 times

View full text PDF listing >>



Composition, spatial characteristics, and prognostic significance of myeloid cell infiltration in pancreatic cancer.

Sara A Väyrynen, Jinming Zhang, Chen Yuan, Juha P Väyrynen, Andressa Dias Costa, Hannah Williams, Vicente Morales-Oyarvide, Mai Chan Lau, Douglas A Rubinson, Richard F Dunne, Margaret M Kozak, Wenjia Wang, Diana Agostini-Vulaj, Michael G Drage, Lauren K Brais, Emma Reilly, Osama E Rahma, Thomas E Clancy, Jiping Wang, David C Linehan, Andrew Aguirre, Charles S Fuchs, Lisa M Coussens, Daniel T Chang, Albert C Koong, Aram F Hezel, Shuji Ogino, Jonathan A Nowak, Brian M Wolpin,

<b>Purpose:</b>While abundant myeloid cell populations in the pancreatic ductal adenocarcinoma (PDAC) microenvironment have been postulated to suppress anti-tumor immunity, the composition of these populations, their spatial locations, and how they relate to patient outcomes are poorly understood.<br><br><b>Experimental design:</b>To generate spatially-resolved tumor and immune cell data at single cell resolution, we ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma.

J Bryan Iorgulescu, Prafulla C Gokhale, Maria C Speranza, Benjamin K Eschle, Michael J Poitras, Margaret K Wilkens, Kara M Soroko, Chhayheng Chhoeu, Aine Knott, Yan Gao, Mary Jane Lim-Fat, Gregory J Baker, Dennis M Bonal, Quang-Dé Nguyen, Gareth R L Grant, Keith L Ligon, Peter K Sorger, E Antonio Chiocca, Ana C Anderson, Paul T Kirschmeier, Arlene H Sharpe, Gordon J Freeman, David A Reardon,

PURPOSE:Dexamethasone, a uniquely potent corticosteroid, is frequently administered to patients with brain tumors to decrease tumor-associated edema, but limited data exist describing how dexamethasone affects the immune system systemically and intratumorally in patients with glioblastoma (GBM), particularly in the context of immunotherapy. EXPERIMENTAL DESIGN:We evaluated the dose-dependent effects of dexamethasone ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



The challenge of combining chemo- and radiotherapy with checkpoint kinase inhibitors.

Linda van Bijsterveldt, Samuel Durley, Timothy Stanley Maughan, Tim Humphrey,

Pre-clinical models of cancer have demonstrated enhanced efficacy of cell cycle checkpoint kinase inhibitors when used in combination with genotoxic agents. This combination therapy is predicted to be exquisitely toxic to cells with a deficient G1/S checkpoint or cells with a genetic predisposition leading to intrinsic DNA replication stress, as ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid cancers with RET Gene Mutations or Fusions.

Diana Bradford, Erin Larkins, Sirisha L Mushti, Lisa Rodriguez, Amy M Skinner, Whitney S Helms, Lauren S L Price, Jeanne Fourie Zirkelbach, Yangbing Li, Jiang Liu, Rosane Charlab, Francisca Reyes Turcu, Dun Liang, Soma Ghosh, Donna Roscoe, Reena Philip, Autumn Zack-Taylor, Shenghui Tang, Paul G Kluetz, Julia A Beaver, Richard Pazdur, Marc R Theoret, Harpreet Singh,

On May 8, 2020, the Food and Drug Administration granted accelerated approval to selpercatinib for 1) adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), 2) adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, and ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma.

Tyler D Hitchman, Gabriella Bayshtok, Emilie Ceraudo, Amanda R Moore, Cindy Lee, Ruobing Jia, Naitao Wang, Mohini R Pachai, Alexander N Shoushtari, Jasmine H Francis, Youxin Guan, Juliet Chen, Matthew T Chang, Barry S Taylor, Thomas P Sakmar, Thomas Huber, Ping Chi, Yu Chen,

PURPOSE:All uveal melanoma and a fraction of other melanoma subtypes are driven by activation of the Gαq pathway. Targeting these melanomas has proven difficult despite advances in the molecular understanding of key driver signaling pathways in the disease pathogenesis. Inhibitors of Gαq have shown promising preclinical results, but their therapeutic ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia/Ib trial.

Amita Patnaik, Timothy A Yap, Hyun Cheol Chung, Maria de Miguel, Yung-Jue Bang, Chia-Chi Lin, Wu-Chou Su, Antoine Italiano, Kay Hoong Chow, Anna M Szpurka, Danni Yu, Yumin Zhao, Michelle Carlsen, Shelly Schmidt, Burkhard Vangerow, Leena Gandhi, Xiaojian Xu, Johanna C Bendell,

PURPOSE:This phase Ia/Ib PACT study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of a new PD-L1 inhibitor, LY3300054, as monotherapy or in combination with ramucirumab, abemaciclib, or merestinib (a type II MET kinase inhibitor) in patients with advanced, refractory solid tumors (NCT02791334). PATIENTS AND METHODS:Patients were enrolled into cohorts ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Therapeutic potential of NTRK3 inhibition in desmoplastic small round cell tumor.

Koichi Ogura, Romel Somwar, Julija Hmeljak, Heather Magnan, Ryma Benayed, Amir Momeni-Boroujeni, Anita S Bowman, Marissa Mattar, Inna Khodos, Elisa de Stanchina, Achim A Jungbluth, Marina Asher, Igor Odintsov, Alifiani B Hartono, Michael LaQuaglia, Emily K Slotkin, Christine A Pratilas, Sean Bong Lee, Lee Spraggon, Marc Ladanyi,

PURPOSE:Desmoplastic small round cell tumor (DSRCT) is a highly lethal intra-abdominal sarcoma of adolescents and young adults. DSRCT harbors a t(11;22)(p13:q12) that generates the EWSR1-WT1 chimeric transcription factor, the key oncogenic driver of DSRCT. EWSR1-WT1 rewires global gene expression networks and activates aberrant expression of targets that together mediate oncogenesis. ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Eradication of T-ALL cells by CD7 targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management.

Shiqi Li, Xinxin Wang, Zhongtao Yuan, Lin Liu, Le Luo, Yu Li, Kun Wu, Jia Liu, Chunhui Yang, Zhimin Li, Duanpeng Wang, Lianjun Shen, Xun Ye, Jiaping He, Cong Han, Youcheng Wang, Dingsong Zhang, Yancheng Dong, Lihua Fang, Yingnian Chen, Martina Sersch, Wei William Cao, Sanbin Wang,

Purpose:Although chimeric antigen receptor T cell (CAR-T) therapy development for B cell malignancies has made significant progress in the last decade, broadening the success to treating T-ALL has been limited. We conducted two clinical trials to verify the safety and efficacy of GC027, an "off-the-shelf" allogeneic CAR-T product targeting T ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



A phase 1 trial of talimogene laherparepvec in combination with neoadjuvant chemotherapy for the treatment of non-metastatic triple-negative breast cancer.

Hatem Soliman, Deanna Hogue, Hyo Sook Han, Blaise Mooney, Ricardo Lima Barros Costa, Marie C Lee, Bethany Niell, Angela Williams, Alec Chau, Shannon Falcon, Nazanin Khakpour, Robert Jared Weinfurtner, Susan Hoover, John Kiluk, Marilin Rosa, Hung Khong, Brian J Czerniecki,

BACKGROUND:Talimogene laherparepvec (TVEC) is an oncolytic herpes simplex 1 virus approved for treatment of melanoma. We hypothesized intratumoral TVEC may enhance response to neoadjuvant chemotherapy (NAC). This manuscript reports the results of a trial combining NAC with TVEC for triple-negative breast cancer (TNBC). METHODS:Stage II-III TNBC patients enrolled in a ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Cobomarsen, an oligonucleotide inhibitor of miR-155, slows DLBCL tumor cell growth in vitro and in vivo.

Eleni Anastasiadou, Anita Seto, Xuan Beatty, Melanie Hermreck, Maud-Emmanuelle Gilles, Dina Stroopinsky, Lauren C Pinter-Brown, Linda Pestano, Cinzia Marchese, David Avigan, Pankaj Trivedi, Diana Escolar, Aimee Jackson, Frank J Slack,

PURPOSE:MicroRNA-155, is an oncogenic miRNA, highly expressed in B-cell malignancies, particularly in the non-Germinal Center B-cell or activated B-cell subtype of Diffuse Large B-cell Lymphoma (non-GCB/ABC-DLBCL), where it is considered a potential diagnostic and prognostic biomarker. Thus, miR-155 inhibition represents an important therapeutic strategy for B-cell lymphomas. In this study, ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.0056 s